论文部分内容阅读
本文为探讨肠化生细胞增殖分型与肿瘤相关基因蛋白产物的关系，应用S—P免疫组织化学方法检测230例胃粘膜病变中增殖细胞核抗原（PCNA）的表达情况，计算细胞增殖指数（PI），检测肠化生细胞中肿瘤相关基因蛋白产物的表达。本级实验显示正常或慢性浅表性胃炎、伴肠化生慢性萎缩性胃炎、伴异型增生慢性萎缩性胃炎以及胃腺癌的PI逐渐增高，差异非常明显（P＜0．01）。根据胃粘膜肠化生细胞的PI分布，进行肠化生细胞的增殖状态分型：高增殖、中增殖、低增殖状态型。此分型与各类胃粘膜病变显示较好的相关性，LPT为正常或基本正常胃粘膜，MPT为胃粘膜良性病变，HPT为胃粘膜癌前病变。HPT肠化生中肿瘤相关基因蛋白产物rasp21、EGFR、h－met的表达以及Ⅲ型肠化生的检出率显著高于MPT、LPT肠化生（P＜0．05）。提示HPT肠化生细胞基因表达的异常率增高，且细胞分化不良，更具胃癌前病变的特征。胃粘膜肠化生细胞的增殖状态分型可作为评价胃癌发生风险的一项有效指标，具有较好的临床应用前景。
In order to investigate the relationship between the proliferation of intestinal metaplasia and tumor associated gene protein products, the expression of proliferating cell nuclear antigen (PCNA) in 230 cases of gastric mucosal lesions was detected by S-P immunohistochemical method, and the cell proliferation index (PI) was calculated. ), Detection of expression of tumor-associated gene protein products in intestinal metaplasia cells. This experiment showed that the PI of normal or chronic superficial gastritis, chronic atrophic gastritis with intestinal metaplasia, chronic atrophic gastritis with adenohyperplasia, and gastric adenocarcinoma was gradually increased, and the difference was very significant (P<0.01). According to the PI distribution of intestinal metaplasia of gastric mucosa, the proliferative state of intestinal metaplasia is classified: high proliferation, medium proliferation, and low proliferation state. This classification showed good correlation with various types of gastric mucosal lesions. LPT was normal or essentially normal gastric mucosa, MPT was benign gastric lesions, and HPT was gastric precancerous lesions. The expression of tumor-associated gene protein products rasp21, EGFR, h-met and type III intestinal metaplasia were significantly higher in HPT intestinal metaplasia than in MPT and LPT intestinal metaplasia (P<0.05). The abnormal rate of HPT intestinal metaplasia gene expression was increased, and the cell differentiation was poor, which was more characteristic of precancerous lesions. Gastric mucosal intestinal metaplasia can be used as an effective index to evaluate the risk of gastric cancer. It has good clinical application prospects.